Likewise, activation of NEK9 (and NEK7) promoted the activation of oncogenic EML4–ALKv3 and V5 fusion proteins that are involved in the progression of certain cancers, including non-small cell lung cancer (NSCLC) and gastric cancer (Figure 3; Table 4) [177]. This evidence concerns the gene EML4 and non-small cell lung carcinoma.